PPMD webinar, page-3

Just so people can be prepared if they view this webinar, Mark Diamond will be a presenter, lol
It does not concern me but maybe those that have issues can desensitize or take a pill or something, beforehand, lol.
(all said lightheartedly )

Parent Project Muscular Dystrophy
Your Host

mce-anchor
About this event
Antisense Therapeutics recently announced that their Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne in non-ambulatory patients has met its primary endpoint, confirming the safety and tolerability of ATL1102 for advancement into a Phase IIb clinical trial. Please join PPMD and Antisense as we host a webinar Wednesday, June 17 at 1 PM ET to discuss Antisense Therapeutics’ clinical program, as well as next steps in the upcoming Phase IIb trial.

Please submit questions in advance to [email protected] (subject line: Antisense Webinar) by Monday, June 15 at 12 PM ET.
About the presenters

Moderator: Pat Furlong
Parent Project Muscular Dystrophy - Founding President & CEO

Nuket Desem
Antisense Therapeutics - Director of Clinical & Regulatory Affairs

Ms Desem has over 25 years’ experience in global regulatory affairs, clinical development and project management obtained through her roles within the pharmaceutical/biotechnology industry, including senior positions in various biotechnology companies. Ms Desem was previously employed at Antisense Therapeutics (2004–2010) as the Company’s Development Director where part of her responsibility was the management of ANP’s clinical trial programs. Major achievements in this role included the successful conduct and completion of the Company’s multinational Phase IIa clinical trial of ATL1102 for the treatment of Multiple Sclerosis. Nuket joins Antisense Therapeutics from Paranta Biosciences, where she held the position of Director Clinical and Regulatory Affairs. Prior to Paranta, Nuket was Senior Manager Development and Regulatory Affairs at Prana Biotechnology.

Mark Diamond
Antisense Therapeutics - CEO

Mark Diamond has over 30 years experience in the pharmaceutical and biotechnology industry. Before joining Antisense Therapeutics Limited as MD and CEO in 2001, Mr. Diamond was employed in the US as Director, Project Planning/Business Development at Faulding Pharmaceuticals. Prior to this he held the positions of Senior Manager, Business Development and In-licensing within Faulding’s European operation based in the UK and International Business Development Manager with Faulding in Australia.